| Feb-2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. | Drilon, Alexander; Siena, Salvatore; Dziadziuszko, Rafal; Barlesi, Fabrice; Krebs, Matthew G; Shaw, Alice T; de Braud, Filippo; Rolfo, Christian; Ahn, Myung-Ju; Wolf, Jürgen; Seto, Takashi; Cho, Byoung Chul; Patel, Manish R; Chiu, Chao-Hua; John, Thomas ; Goto, Koichi; Karapetis, Christos S; Arkenau, Hendrick-Tobias; Kim, Sang-We; Ohe, Yuichiro; Li, Yu-Chung; Chae, Young K; Chung, Christine H; Otterson, Gregory A; Murakami, Haruyasu; Lin, Chia-Chi; Tan, Daniel S W; Prenen, Hans; Riehl, Todd; Chow-Maneval, Edna; Simmons, Brian; Cui, Na; Johnson, Ann; Eng, Susan; Wilson, Timothy R; Doebele, Robert C |
| 29-Apr-2022 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. | Drilon, Alexander; Chiu, Chao-Hua; Fan, Yun; Cho, Byoung Chul; Lu, Shun; Ahn, Myung-Ju; Krebs, Matthew G; Liu, Stephen V; John, Thomas ; Otterson, Gregory A; Tan, Daniel S W; Patil, Tejas; Dziadziuszko, Rafal; Massarelli, Erminia; Seto, Takashi; Doebele, Robert C; Pitcher, Bethany; Kurtsikidze, Nino; Heinzmann, Sebastian; Siena, Salvatore |
